Nosopharm’s anti-infective pipeline focuses on the treatment of infectious diseases, particularly in the context of antimicrobial resistance.
Our lead R&D programs are based on our unique expertise in the biomining of the bacteria Photorhabdus and Xenorhabdus.
NOSO-502 IS NOSOPHARM’S FIRST CLINICAL CANDIDATE IN THE NEW CLASS OF ANTIBIOTICS CALLED ODILORHABDINS AND DISCOVERED FROM A XENORHABDUS BACTERIA.
NOSO-502 is intended for the treatment of the main hospital-acquired infections caused by the multidrug-resistant Enterobacteriaceae : Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp.
NOSO-502 inhibits the bacterial ribosome with a new mechanism of action. It is active against the Carbapenem-Resistant Enterobacteriaceae (CRE), whatever their profile of carbapenemase production. These pathogens are responsible for severe and life-threatening hospital-acquired infections: the WHO classifies them as critical priority pathogens for which new antibiotics are urgently needed.
NOSO-2G is a second-generation Odilorhabdin antibiotic at early preclinical stage. It is active against Carbapenem-Resistant Pseudomonas aeruginosa and Carbapenem-Resistant Acinetobacter baumannii.
These pathogens are responsible for life-threatening respiratory hospital-acquired infections: the WHO classifies them as critical priority pathogens for which new antibiotics are urgently needed. NOSO-2G is intended for the treatment of hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP), including infections caused by multidrug-resistant pathogens.
Nosopharm develops other R&D programs in the field of infectious diseases stemming from its Photorhabdus & Xenorhabdus based drug discovery platform. Screening campaigns are on-going to discover novel classes of antifungals for the treatment of invasive candidiasis caused by the emerging multidrug-resistant pathogens such as Candida auris and Candida glabrata.